Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Change in Account Payables (2017 - 2025)

Historic Change in Account Payables for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to $2.4 million.

  • Protagonist Therapeutics' Change in Account Payables rose 78112.68% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 5522.39%. This contributed to the annual value of $842000.0 for FY2024, which is 12935.84% up from last year.
  • Latest data reveals that Protagonist Therapeutics reported Change in Account Payables of $2.4 million as of Q3 2025, which was up 78112.68% from $375000.0 recorded in Q2 2025.
  • Protagonist Therapeutics' 5-year Change in Account Payables high stood at $5.6 million for Q1 2022, and its period low was -$10.9 million during Q3 2021.
  • Over the past 5 years, Protagonist Therapeutics' median Change in Account Payables value was $381000.0 (recorded in 2023), while the average stood at $116631.6.
  • Its Change in Account Payables has fluctuated over the past 5 years, first tumbled by 111946.0% in 2021, then skyrocketed by 78112.68% in 2025.
  • Protagonist Therapeutics' Change in Account Payables (Quarter) stood at $452000.0 in 2021, then plummeted by 338.05% to -$1.1 million in 2022, then surged by 44.52% to -$597000.0 in 2023, then crashed by 139.53% to -$1.4 million in 2024, then surged by 269.09% to $2.4 million in 2025.
  • Its Change in Account Payables stands at $2.4 million for Q3 2025, versus $375000.0 for Q2 2025 and $1.2 million for Q1 2025.